BackgroundAgonistic anti-CD40 antibodies and related CD40 agonist biologics are being developed across multiple solid tumors using diverse biologic formats, delivery routes, and combination regimens. Safety is central to their clinical development but …
BackgroundSecondary immunodeficiency (SID) arises from malignancy, immunomodulatory therapies, organ dysfunction, chronic infection, malnutrition, and aging. Despite its increasing prevalence, SID remains conceptualized within disease-specific silos, r…
ObjectiveTo compare the efficacy and safety of topical ocular therapies for Sjögren’s syndrome–related dry eye disease.MethodsPubMed, Embase, Web of Science, Cochrane Central, CNKI, Wanfang, VIP, and CBM were searched from inception to April 29, 2026. …
PurposeTo systematically assess the prognostic significance of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG PET/CT) metabolic parameters in patients with non-small cell lung cancer (NSCLC) undergoing immun…
BackgroundObesity correlates closely with type 2 diabetes mellitus (T2DM), with central adiposity, dyslipidemia and chronic low-grade inflammation as typical pathological features. Physical exercise is recommended as a safe core non-pharmacological int…
Cervical cancer, a human papillomavirus (HPV) -driven malignancy with inherent viral antigenicity, serves as a key model in immuno-oncology. Yet, the variable efficacy of immune checkpoint inhibitors highlights a critical gap: the lack of preclinical m…
BackgroundComplement C3 is a key effector molecule of the innate complement system, which participates in inflammatory responses, immune regulation and the maintenance of metabolic homeostasis. Consistency and evidence grade regarding the association b…
BackgroundRashes in patients treated with epidermal growth factor receptor inhibitors (EGFRIs) are closely related to better clinical outcomes. Multiple randomized controlled trials have evaluated rashes caused by EGFRIs. We conducted a meta-analysis o…
BackgroundBispecific antibodies (bsAbs) have rapidly emerged as one of the most promising therapeutic strategies in oncology because of their ability to simultaneously engage multiple molecular targets and enhance antitumor immunity. Although the numbe…
BackgroundChimeric antigen receptor (CAR) T-cell therapy in solid tumors is hindered by the immunosuppressive tumor microenvironment and by toxicities associated with viral-vector manufacturing. Non-viral gene delivery platforms have emerged as a poten…
